Clinical Trial Update: Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating pembrolizumab with and without healthy donor FMT plus lenvatinib in relapsed/refractory melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Diwakar Davar | Conditions: PD-1 Refractory Advanced Melanoma | Phase 2 | Status: WITHDRAWN